RecruitingPhase 1NCT07694557

A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection

A Phase 1, Randomized, Double-Blind, Ascending-Dose Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Respiratory Syncytial Virus mRNA Vaccine YKYY025 Injection in Healthy Adult Participants

Sponsor

Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.

Enrollment

180 participants

Start Date

Jul 29, 2026

Study Type

INTERVENTIONAL

Conditions

Respiratory Syncytial Virus (RSV)

Summary

A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called YKYY025 Placebo group and a drug called YKYY025 group for people with respiratory syncytial virus (rsv). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGYKYY025 group

intramuscular, a single intramuscular injection of the corresponding dose of YKYY025 for injection

DRUGYKYY025 Placebo group

intramuscular, a single intramuscular injection of the corresponding dose of YKYY025 Placebo

Locations(1)

Anning First People's Hospital

Anning, Yunnan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07694557

Related Trials

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults

NCT07768345

A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults

NCT07764237

A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF

NCT07653100

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

NCT074826578 locations

Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease

NCT068518066 locations